SHANGHAI – Glaxosmithkline plc has had a rough couple of years in China. But the big pharma is seeking now to emerge from the dust of a scandal that forced it to pay a $3 billion fine for giving bribes to boost drug sales and led to suspended prison sentences for five executives and the embarrassing deportation of GSK's China general manager.